Our findings indicated a notable upregulation of RBMX2 in lung cancer, specifically in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) (Figure 5B). Here, RBMX2 is linked to squamous cell lung carcinoma.